{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:41:04Z","timestamp":1789137664227,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013460","name":"Taiwan Liver Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013460","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.jhep.2020.01.027","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T02:22:13Z","timestamp":1581646933000},"page":"62-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV\/HCV co-infection"],"prefix":"10.1016","volume":"73","author":[{"given":"Ming-Lun","family":"Yeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-I.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinta A.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Hsuan","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Shan","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Cheng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Chien","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yen","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zu-Yau","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinn-Cherng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee-Fu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Yen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond T.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2020.01.027_bib1","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2017.05.008","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"67","author":"Lok","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.01.027_bib2","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/hep.20240","article-title":"HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects","volume":"39","author":"Yuen","year":"2004","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2020.01.027_bib3","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0168-8278(03)00139-9","article-title":"Natural history of hepatitis B","volume":"39","author":"Fattovich","year":"2003","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.01.027_bib4","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","article-title":"Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection","volume":"60","author":"Buti","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2020.01.027_bib5","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2020.01.027_bib6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1053\/j.gastro.2008.10.049","article-title":"Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses","volume":"136","author":"Liu","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.01.027_bib7","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1002\/hep.26266","article-title":"Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up","volume":"57","author":"Yu","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.01.027_bib8","doi-asserted-by":"crossref","first-page":"e1837","DOI":"10.1097\/MD.0000000000001837","article-title":"Personalized therapy of chronic hepatitis C and B dually infected patients with pegylated interferon plus ribavirin: a randomized study","volume":"94","author":"Yeh","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jhep.2020.01.027_bib9","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/infdis\/jiy648","article-title":"Pretreatment hepatitis B viral load predicts long-term hepatitis B response after anti-hepatitis C therapy in hepatitis B\/C dual-infected patients","volume":"219","author":"Yeh","year":"2019","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhep.2020.01.027_bib10","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12072-016-9717-6","article-title":"APASL consensus statements and recommendation on treatment of hepatitis C","volume":"10","author":"Omata","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2020.01.027_bib11","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.01.027_bib12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.01.027_bib13","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1053\/j.gastro.2017.11.011","article-title":"Efficacy of ledipasvir and sofosbuvir treatment of HCV infection in patients coinfected with HBV","volume":"154","author":"Liu","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.01.027_bib14","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1111\/jgh.13771","article-title":"Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals","volume":"32","author":"Yeh","year":"2017","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.01.027_bib15","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S2468-1253(18)30002-5","article-title":"Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis","volume":"3","author":"Mucke","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.01.027_bib16","doi-asserted-by":"crossref","first-page":"792","DOI":"10.7326\/M17-0377","article-title":"Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. Food and Drug administration adverse event reporting system","volume":"166","author":"Bersoff-Matcha","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2020.01.027_bib17","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jcv.2014.04.008","article-title":"Comparison of the Abbott RealTime HBV assay with the Roche cobas AmpliPrep\/cobas TaqMan HBV assay for HBV DNA detection and quantification","volume":"60","author":"Yeh","year":"2014","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.jhep.2020.01.027_bib18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jcv.2011.07.007","article-title":"Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C","volume":"52","author":"Vermehren","year":"2011","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.jhep.2020.01.027_bib19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jhep.2011.03.029","article-title":"Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon\/ribavirin","volume":"56","author":"Huang","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.01.027_bib20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00109-015-1348-1","article-title":"MicroRNA let-7g cooperates with interferon\/ribavirin to repress hepatitis C virus replication","volume":"94","author":"Chou","year":"2016","journal-title":"J\u00a0Mol Med (Berl)"},{"key":"10.1016\/j.jhep.2020.01.027_bib21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.antiviral.2014.03.003","article-title":"Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection","volume":"105","author":"Hsi","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2020.01.027_bib22","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.01.027_bib23","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1038\/ctg.2017.51","article-title":"Seven-year treatment outcome of entecavir in a real-world cohort: effects on clinical parameters, HBsAg and HBcrAg levels","volume":"8","author":"Lam","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"issue":"2","key":"10.1016\/j.jhep.2020.01.027_bib24","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s10620-018-5281-3","article-title":"A\u00a0comparison between community and academic practices in the USA in the management of chronic hepatitis B patients receiving entecavir: results of the ENUMERATE study","volume":"64","author":"Lee","year":"2019","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2020.01.027_bib25","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.01.027_bib26","doi-asserted-by":"crossref","first-page":"e20752","DOI":"10.1371\/journal.pone.0020752","article-title":"Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses","volume":"6","author":"Yeh","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2020.01.027_bib27","doi-asserted-by":"crossref","first-page":"e0186213","DOI":"10.1371\/journal.pone.0186213","article-title":"Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy","volume":"12","author":"Burchill","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2020.01.027_bib28","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1136\/gutjnl-2015-310033","article-title":"Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNalpha","volume":"66","author":"Serti","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2020.01.027_bib29","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/jvh.12836","article-title":"IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR","volume":"25","author":"Carlton-Smith","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2020.01.027_bib30","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/jvh.13041","article-title":"Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infection","volume":"26","author":"Holmes","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2020.01.027_bib31","doi-asserted-by":"crossref","first-page":"11291","DOI":"10.18632\/oncotarget.24129","article-title":"The IL-6\/STAT3 pathway upregulates microRNA-125b expression in hepatitis C virus infection","volume":"9","author":"Dai","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhep.2020.01.027_bib32","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/jvh.12522","article-title":"The expression of miR-125b-5p is increased in the serum of patients with chronic hepatitis B infection and inhibits the detection of hepatitis B virus surface antigen","volume":"23","author":"Ninomiya","year":"2016","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2020.01.027_bib33","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/jvh.12470","article-title":"Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir\/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects","volume":"23","author":"Waring","year":"2016","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2020.01.027_bib34","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1096\/fj.11-187781","article-title":"A\u00a0liver-specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication","volume":"25","author":"Chen","year":"2011","journal-title":"FASEB J"},{"key":"10.1016\/j.jhep.2020.01.027_bib35","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/jmv.25238","article-title":"Circulating microRNA-122 levels are important predictor of hepatitis B virus surface antigen seroclearance","volume":"90","author":"Akuta","year":"2018","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.jhep.2020.01.027_bib36","doi-asserted-by":"crossref","first-page":"33816","DOI":"10.1038\/srep33816","article-title":"MicroRNA-122 as a predictor of HBsAg seroclearance in hepatitis B and C dual infected patients treated with interferon and ribavirin","volume":"6","author":"Yen","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2020.01.027_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/v10110645","article-title":"HCV-specific T cell responses during and after chronic HCV infection","volume":"10","author":"Luxenburger","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.jhep.2020.01.027_bib38","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.antiviral.2017.08.016","article-title":"Immune responses in DAA treated chronic hepatitis C\u00a0patients with and without prior RG-101 dosing","volume":"146","author":"van der Ree","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2020.01.027_bib39","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s12072-019-09988-7","article-title":"APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation","volume":"13","author":"Kanda","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2020.01.027_bib40","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.cgh.2015.06.002","article-title":"Association between level of hepatitis B surface antigen and relapse after entecavir therapy for chronic hepatitis B virus infection","volume":"13","author":"Chen","year":"2015","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882782030074X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882782030074X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T19:15:35Z","timestamp":1716664535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882782030074X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S016882782030074X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2020.01.027","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV\/HCV co-infection","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2020.01.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}